Startups
CAVU Biotherapies focuses on quality science and innovative immunotherapies to treat dogs and cats with cancer and other diseases.
Safe DePawsit by CAVU provides a "forever" sample of your pet's healthy immune system for future immunotherapy use by cryobanking or freezing your pet's white blood cells.
IHAV By CAVU is a new in depth snapshot of your pet's immune system that provides more detailed white blood cell information compared with the standard CBC.
Many of CAVU's products are covered by pet insurance and Care Credit. CAVU also offers direct payment plans.
Safe DePawsit by CAVU provides a "forever" sample of your pet's healthy immune system for future immunotherapy use by cryobanking or freezing your pet's white blood cells.
IHAV By CAVU is a new in depth snapshot of your pet's immune system that provides more detailed white blood cell information compared with the standard CBC.
Many of CAVU's products are covered by pet insurance and Care Credit. CAVU also offers direct payment plans.
Overview
Location
United States, Texas, Houston
Employees
1-10
Phone
+1 713-380-2758
Founded date
2015
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 27, 2020 | 11 startups pitch top Houston angel investors at biannual summit | The Houston Angel Network checked in with their investors and portfolio companies at their biannual Houston Angel Summit that gathered HAN members, local investors, and startup founders for a day full of educational opportunities, pitches, ... |
| Apr 11, 2019 | 5 Houston biotech companies taking health care to new levels | Houston is the home of the largest medical center in the world, so it comes as no surprise that the Bayou City is also home to breakthrough technologies. Here are five Houston companies developing some of this biotech advancements. Moleculi... |
| Nov 23, 2018 | Houston-based veterinary biotech startup modernizes cancer treatments for dogs | More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies recently accomplished a significant milestone. In October, CAVU's specialized immunotherapy was administered to its first cancer patient: a... |
| Apr 30, 2018 | Cancer immunotherapy research receives £1m Innovate UK funding | PhoreMost Limited and NeoPhore Limited have announced the companies will receive £1 million of funding to support the development of a novel small-molecule cancer immunotherapy programme, following the award of a Biomedical Catalyst grant i... |
| Dec 11, 2017 | Gilead backs $60M Hookipa round to fund immunotherapy R&D | Gilead has joined Boehringer Ingelheim and Takeda on the list of investors in Hookipa Biotech. The big biotech participated in a $60 million (€50 million) series C intended to equip Hookipa to advance its cytomegalovirus (CMV) vaccine and c... |
| Sep 30, 2016 | Langer’s cell engineering immunotherapy play SQZ nabs $16M | SQZ Biotech has closed a $16 million Series B round to develop next-gen cell therapies. The financing will go to preclinical development for immunotherapy programs in oncology and other diseases. Founded in 2013, the Boston, MA-based compan... |
| Dec 4, 2013 | Immunotherapy startup lands $120M Series A for cancer-killing drugs | Once-rival researchers from the Fred Hutchinson Cancer Research Center and Memorial Sloan-Kettering Cancer Center have decided to join forces and dive into drug development, hauling in a massive $120 million Series A round to advance "... |
| Feb 14, 2013 | Third Rock bankrolls cancer immunotherapy upstart with $47M A round | Third Rock Ventures is committing $47 million to launch a biotech focused on cancer immunotherapeutics, one of the hottest fields in drug R&D today. This is a classic startup from the crew that emerged from Millennium to launch their ow... |
| Biopharma using fungal carbohydrate for innovative cancer immunotherapy raises $3.6M | Biopharma startup ImmuneXcite is developing an immunotherapy to treat cancer that depends an innovative catalyst — a fungal carbohydrate. The life science innovation relies on neutrophils, white blood cells that represent the body’s first d... |
Show more
Reviews 0
FAQ about CAVU Biotherapies
When was CAVU Biotherapies founded?
CAVU Biotherapies was founded in 2015.
What has the press written about CAVU Biotherapies?
Parsers VC has collected 14 articles mentioning CAVU Biotherapies, among them “11 startups pitch top Houston angel investors at biannual summit” (Feb 27, 2020) and “5 Houston biotech companies taking health care to new levels” (Apr 11, 2019).
Is CAVU Biotherapies still active?
Yes, CAVU Biotherapies is active; its latest activity on Parsers VC dates from Jun 27, 2023.